EMEA-002125-PIP01-17

Key facts

Invented name
Tagrisso
Active substance
Osimertinib (as mesylate)
Therapeutic area
Oncology
Decision number
P/0222/2017
PIP number
EMEA-002125-PIP01-17
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 855327591
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating